Rotigotine transdermal patch    (DrugBank: Rotigotine)

1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease16

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
16 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-194763
22/4/201920/05/2019Safety and PK study of LY03003An open-label study in Japanese patients with Parkinson's disease to evaluate the safety, pharmacokinetics and preliminary efficacy of LY03003 following intramuscular injections and its comparative bioavailability to Rotigotine transdermal patch. Parkinson's DiseaseIntervention name : Rotigotine
INN of the intervention : Rotigotine
Dosage And administration of the intervention : LY03003 IM injections 14, 28 and 56 mg/week.
Control intervention name : Rotigotine
INN of the control intervention : Rotigotine
Dosage And administration of the control intervention : Rotigotine transdermal patch applications 4.5, 9 and 18 mg/day.
Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.NULLcomplete20BOTH32Phase 1Japan
2JPRN-UMIN000033409
2018/07/0217/07/2018Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial. Parkinson's diseasePretreatment by heparinoid
In the pretreatment group, heparinoid is applied daily to the sites (shoulder, upper arm, abdomen, thigh, buttocks on both sides) to be applied rotigotine transdermal patch from the beginning of 1 week before. The dose is one finger tip unit (about 0.5 g) for two palms. The period is 8 weeks.
Non-pretreatment by heparinoid.
The non-pretreatment group use rotigotine without using heparinoid. The period is 8 weeks.
Wakayama Medical UniversityNULLRecruiting20years-old85years-oldMale and Female20Phase 1Japan
3NCT02365870
(ClinicalTrials.gov)
August 201611/2/2015Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational TreatmentAnxiety in Parkinson's: Use of Quantitative Methods to Guide Rational TreatmentAnxiety Disorders;Parkinson DiseaseDrug: rotigotine transdermal patch;Drug: placeboJohns Hopkins UniversityNational Institute on Aging (NIA)Terminated21 Years89 YearsAll4Phase 4United States
4NCT01711866
(ClinicalTrials.gov)
September 201218/10/2012A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's DiseaseAn Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4Advanced Idiopathic Parkinson's DiseaseDrug: RotigotineUCB BIOSCIENCES GmbHOtsuka Pharmaceutical Co., Ltd.Completed30 Years80 YearsAll87Phase 4United States;Korea, Republic of;Malaysia;Singapore;Taiwan
5NCT01646255
(ClinicalTrials.gov)
July 201218/7/2012Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease PatientsA Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On LevodopaIdiopathic Parkinson's DiseaseDrug: Rotigotine;Drug: Placebo Patch;Drug: L-dopaUCB PharmaUCB Trading (Shanghai) Co. Ltd.Completed30 YearsN/AAll346Phase 3China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01646268
(ClinicalTrials.gov)
July 201218/7/2012Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease PatientsA Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's DiseaseIDIOPATHIC PARKINSON'S DISEASEDrug: Rotigotine;Drug: Placebo PatchUCB PharmaNULLCompleted30 YearsN/AAll249Phase 3China
7NCT01338896
(ClinicalTrials.gov)
April 201118/4/2011Study to Compare Adhesiveness of Two Different Rotigotine Patch FormulationsA Multicenter, Randomized, Double-blind, Two-way Cross-over Study to Compare the Adhesiveness of Two Different Rotigotine Patch Formulations in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: Rotigotine transdermal patchUCB PharmaNULLCompleted18 YearsN/ABoth56Phase 1Austria;Germany;United Kingdom
8NCT00594464
(ClinicalTrials.gov)
September 200721/12/2007A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing SurgeryAn Explorative, Multicenter, Open-label Pilot Trial With Neupro® (Rotigotine Transdermal Patch) Once Daily Treatment Administered Perioperatively in Patients With Idiopathic Parkinson's DiseaseParkinson's DiseaseDrug: RotigotineUCB PharmaNULLCompleted18 Years80 YearsAll14Phase 4Germany
9EUCTR2006-005438-19-DE
(EUCTR)
12/06/200728/03/2007An explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease. - NEUPOSAn explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease. - NEUPOS idiopathic Parkinson´s disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease
Trade Name: Neupro 2 mg/24 h transdermal patch
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4 mg/24 h transdermal patch
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6 mg/24 h transdermal patch
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8 mg/24 h transdermal patch
INN or Proposed INN: Rotigotine
SCHWARZ PHARMA Deutschland GmbHNULLNot RecruitingFemale: yes
Male: yes
30Germany
10EUCTR2004-002598-21-GB
(EUCTR)
02/03/200507/07/2005A phase 3b, open-label. multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's diseaseA phase 3b, open-label. multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease Idiopathic Parkinson's diseaseProduct Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Schwarz Biosciences GmbHNULLNot RecruitingFemale: yes
Male: yes
50Phase 3Austria;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2004-002598-21-AT
(EUCTR)
22/12/200417/11/2004A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's diseaseA phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease Parkinson's DiseaseProduct Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM 962
INN or Proposed INN: Rotigotine
Schwarz Biosciences GmbHNULLNot RecruitingFemale: yes
Male: yes
50Phase 3bAustria;United Kingdom
12EUCTR2004-002609-66-IT
(EUCTR)
21/12/200403/03/2006A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson s diseaseA phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson s disease Idiopathic Parkinson Disease in early stage
MedDRA version: 6.1;Level: PT;Classification code 10061536
Product Name: rotigotine
Product Code: SPM 926
Trade Name: REQUIP 21 CPR 0,25 MG
INN or Proposed INN: Ropinirole
Product Name: rotigotine
Product Code: SPM 962
Trade Name: REQUIP 21 CPR 0,5 MG
INN or Proposed INN: Ropinirole
Product Name: rotigotine
Product Code: SPM 962
Product Name: rotigotine
Product Code: SPM 962
Trade Name: REQUIP 21 CPR 1 MG
INN or Proposed INN: Ropinirole
Trade Name: REQUIP 21 CPR 2 MG
INN or Proposed INN: Ropinirole
SCHWARZ PHARMANULLNot RecruitingFemale: yes
Male: yes
60Phase 3Germany;Italy
13EUCTR2004-002609-66-DE
(EUCTR)
06/12/200422/04/2005A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's diseaseA phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's disease Parkinson's DiseaseProduct Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Product Name: Rotigotine
Product Code: SPM962
INN or Proposed INN: Rotigotine
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Trade Name: Requip
Product Name: Requip
INN or Proposed INN: Ropinirole
Schwarz Biosciences GmbHNULLNot RecruitingFemale: yes
Male: yes
60Phase 3Germany;Italy
14NCT00243945
(ClinicalTrials.gov)
December 200424/10/2005A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's DiseaseA Phase 3b, Open-Label, Multicenter, Multinational Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders in Patients With Idiopathic Parkinson's DiseaseIDIOPATHIC PARKINSON'S DISEASEDrug: RotigotineUCB PharmaNULLCompleted18 YearsN/ABoth58Phase 3Germany
15NCT00243971
(ClinicalTrials.gov)
November 200424/10/2005A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's DiseaseA Phase 3, Randomized, Open-Label, Two-Arm, Parallel-Group, Multicenter, Multinational Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's DiseaseParkinson's DiseaseDrug: SPM 962UCB PharmaNULLCompleted18 YearsN/ABothPhase 3Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2009-014341-84-DE
(EUCTR)
07/10/2009Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastrointestinal symptoms.Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastrointestinal symptoms. idiopathic Parkinson's disease
MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease
Trade Name: Neupro 2 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 2mg/24h(10cm2)
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 4mg/24h (20cm2)
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 6mg/24h (30cm2)
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 8mg/24h (40cm2)
INN or Proposed INN: rotigotine
Schwarz Pharma Deutschland GmbH, UCB GroupNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Germany